BURKITT LYMPHOMA

This early-stage study tests a mix of six drugs (called ViPOR-P) in adults with B-cell lymphomas that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. About 34 participants will take pills and receive infusions o…

This study tests a new way to do stem cell transplants for children and young adults (up to age 22) with blood cancers like leukemia. Doctors remove certain immune cells from donated stem cells to lower the risk of graft-versus-host disease, a serious complication. The goal is to…

This study tests whether adding the targeted drug rituximab to standard chemotherapy can improve outcomes for children and teens with aggressive B-cell lymphoma or leukemia. About 650 participants from Europe will receive different treatment schedules to find the best balance of …

This early study tests a new gene therapy called INT2104 in 10 adults with B-cell cancers that have come back or not responded to treatment. The therapy is given as a single IV infusion and works by instructing the body to create its own cancer-fighting T cells and natural killer…

This early-phase study tests the safety of specially engineered immune cells (armored CAR T cells) in people with certain blood cancers that have not responded to standard treatments. The cells are made from the patient's own blood and designed to better target and attack cancer …

This study tests whether adding four doses of rituximab to an intensified chemotherapy regimen improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. About 200 participants in China will receive the new treatment, and research…

This study tests a new stem cell treatment (MGTA-456) made from umbilical cord blood for people with high-risk blood cancers like leukemia and lymphoma. About 22 patients will receive high-dose chemotherapy followed by the stem cell infusion. The goal is to see if this treatment …

This study tests a stem cell transplant method that removes certain immune cells (T and B cells) from donated stem cells before giving them to patients with blood cancers like leukemia or lymphoma. The goal is to help the new cells grow (engraft) while reducing the risk of graft-…

This early-phase trial tests a new antibody drug called IMT-009, given alone or with the cancer pill fruquintinib, in about 67 people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand si…

This early-phase trial tests a new drug, loncastuximab tesirine, combined with a standard chemotherapy regimen (DA-EPOCH-R) in 11 adults with aggressive B-cell lymphomas. The main goal is to find the safest dose and check for side effects. It is not yet known if this combination …

This early-phase trial is testing a new type of immunotherapy called tri-specific CAR T-cells that target three proteins (CD19, CD20, CD22) on cancer cells. It is for adults with B-cell lymphomas that have come back or not responded to standard treatments. The study will enroll 1…

This study looks at whether a liquid biopsy (a simple test that checks for cancer DNA in spinal fluid) can better detect and monitor brain involvement in people with high-risk B-cell non-Hodgkin lymphoma. Researchers will compare this new method to standard tests in 64 newly diag…

This study looks back at medical records of 500 adults with aggressive B-cell lymphoma that has a MYC gene change. Researchers want to see if a stronger chemotherapy plan called CARMEN leads to better survival and remission rates compared to other treatments. Since it's a review …

This study looks at the biology of B-cell lymphoma in children and teens to better understand the disease and long-term effects of treatment. About 128 participants will provide tumor and blood samples for genetic analysis. The goal is not to test a new drug, but to gather knowle…